You are here

oncology

ASCO and Friends of Cancer Research Draft 5 Guidances for FDA

ASCO and Friends of Cancer Research Draft 5 Guidances for FDA

RAPS.org

clinical trials

Friends of Cancer Research

Flag link:

Touting its manufacturing strengths, Tot Biopharm raises $102M mega-round to ramp up cancer R&D

Touting its manufacturing strengths, Tot Biopharm raises $102M mega-round to ramp up cancer R&D

Endpoints

Flag link:

Big pharma proves that oncology pays as workforces shrink

Big pharma proves that oncology pays as workforces shrink

EP Vantage

Flag link:

IBM Watson Health, VA extend precision oncology partnership deal

IBM Watson Health, VA extend precision oncology partnership deal

Mass Device

artificial intelligence

Veterans Affairs

Flag link:

Arcus Biosciences Announces That Taiho Pharmaceutical Has Exercised Its Option to Develop and Commercialize AB928 in Its Territories

Arcus Biosciences Announces That Taiho Pharmaceutical Has Exercised Its Option to Develop and Commercialize AB928 in Its Territories

CP Wire

Arcus Biosciences

Taiho Pharmaceutical

Flag link:

Lilly Oncology’s strategy? Listen to tough talk from patients—and save data for later

Lilly Oncology’s strategy? Listen to tough talk from patients—and save data for later

Fierce Pharma

Flag link:

China speeds cancer drug price cuts amid outcry over smuggled Indian generics

China speeds cancer drug price cuts amid outcry over smuggled Indian generics

Fierce Pharma

Flag link:

Latecomer Sanofi looks to catch next wave of cancer therapies

Latecomer Sanofi looks to catch next wave of cancer therapies

Reuters

immuno-oncology

Flag link:

Is ASCO Sending Mixed Messages On Cancer Drug Value?

Is ASCO Sending Mixed Messages On Cancer Drug Value?

Forbes

Flag link:

Sanofi says on track to regain solid position in cancer drugs

Sanofi says on track to regain solid position in cancer drugs

Reuters

molecular oncology

Flag link:

BIO18: Oncology surplus could drive down values

BIO18: Oncology surplus could drive down values

Biopharma Dive

Flag link:

Biotech Firm Grail Takes The First Steps In Its Quest For A Blood Test For Cancer

Biotech Firm Grail Takes The First Steps In Its Quest For A Blood Test For Cancer

Forbes

Flag link:

FDA Calls for Including Adolescents in Adult Oncology Trials

FDA Calls for Including Adolescents in Adult Oncology Trials

RAPS.org

clinical trials

Flag link:

IDO Don’ts: After Immunotherapy Failure, Experts Say Slow Down

IDO Don’ts: After Immunotherapy Failure, Experts Say Slow Down

Xconomy

Flag link:

Half of orphan drug sales to come from cancer, Evaluate finds

Half of orphan drug sales to come from cancer, Evaluate finds

Biopharma Dive

Flag link:

Cancer drug spending climbs, with top winners earning lion's share

Cancer drug spending climbs, with top winners earning lion's share

Biopharma Dive

Bristol-Myers Squibb

Flag link:

Lilly's cancer business loses its chief just as it's leaning on oncology for growth

Lilly's cancer business loses its chief just as it's leaning on oncology for growth

Fierce Pharma

Flag link:

Pfizer culls 5 experimental cancer trials and an acne drug in Q1 clear out

Pfizer culls 5 experimental cancer trials and an acne drug in Q1 clear out

Fierce Biotech

Flag link:

Shire's oncology exit weighs on potential Takeda bid

Shire's oncology exit weighs on potential Takeda bid

Biopharma Dive

Flag link:

Servier buys Shire’s oncology unit for $2.4B in the run-up to Takeda’s final buyout offer — if it makes one

Servier buys Shire’s oncology unit for $2.4B in the run-up to Takeda’s final buyout offer — if it makes one

Endpoints

Flag link:

Pages